Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CNR1 | P21554 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438078 | 1.00 | ALDH1A1 (0.61) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL18853734 | 0.96 | ALDH1A1 (0.57) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12116936 | 0.96 | ALDH1A1 (0.57) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL10087784 | 0.96 | ALDH1A1 (0.57) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12116948 | 0.96 | FAAH (0.55) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12414973 | 0.96 | FAAH (0.55) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL10087783 | 0.93 | NR1I2 (0.55) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12438067 | 0.93 | NR1I2 (0.55) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12438061 | 0.92 | PRKCA (0.56) | ALDH1A1FAAHMAPTCNR1HPGD | |
| SCHEMBL12116939 | 0.92 | PRKCA (0.56) | ALDH1A1FAAHMAPTCNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-03 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-12-31 | — | — | US | disclosed |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | MORGAN STANLEY SENIOR FUNDING, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9107911-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-18 | — | — | US | disclosed |
| US-8796276-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8431576-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-04-30 | — | — | US | disclosed |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LIMITED | 2013-04-18 | — | — | US | disclosed |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | ALKERMES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | ALDH1A1 113/4885FAAH 3072/4885MAPT 3460/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | ALDH1A1 113/4885FAAH 3072/4885MAPT 3460/4885 |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | ALDH1A1 1082/4885FAAH 203/4885MAPT 2880/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | ALDH1A1 1082/4885FAAH 203/4885MAPT 2880/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | ALDH1A1 1082/4885FAAH 203/4885MAPT 2880/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | ALDH1A1 432/4885FAAH 193/4885MAPT 1129/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | ALDH1A1 760/4885FAAH 164/4885MAPT 363/4885 |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | ALDH1A1 172/4885FAAH 735/4885MAPT 3806/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | ALDH1A1 1082/4885FAAH 203/4885MAPT 2880/4885 |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | ALDH1A1 172/4885FAAH 735/4885MAPT 3806/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ALDH1A1 599/4885FAAH 565/4885MAPT 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.